Gut bacteria cocktail aims to tame ulcerative colitis
NCT ID NCT07296315
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 4 times
Summary
This study tests a new medicine called MH002, which contains live bacteria meant to restore gut health in people with mild-to-moderate ulcerative colitis. About 204 adults whose current treatment isn't working well enough will receive either a low dose, high dose, or placebo capsule daily for 12 weeks. The main goal is to see if MH002 can reduce gut inflammation and improve symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MH002 (a live bacterial product made from 6 natural gut bacteria strains)
- What this could lead to
- If successful, this could provide a new treatment option for people with mild-to-moderate ulcerative colitis that is not well controlled by current medications.
- What could go wrong
- This is a Phase 2 trial with only 204 participants, so results are still early. The treatment may not work better than placebo, and long-term safety is not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
ARA Professionals
RECRUITINGMiami, Florida, 33155, United States
-
American Hospital Network LLC
RECRUITINGTbilisi, 0102, Georgia
-
Aversi Clinic LLC
RECRUITINGTbilisi, 0160, Georgia
-
Cross Creek Medical Clinic
RECRUITINGFayetteville, North Carolina, 28304, United States
-
JSC Georgian Clinics
RECRUITINGKutaisi, 4600, Georgia
-
K. Eristavi National Center of Experimental and Clinical Surgery JSC
RECRUITINGTbilisi, 0159, Georgia
-
LEPL The First University Clinic of Tbilisi State Medical University
RECRUITINGTbilisi, 0178, Georgia
-
LLC The First Medical Center
RECRUITINGTbilisi, 0180, Georgia
-
LTD Institute of Clinical Cardiology
RECRUITINGTbilisi, 0159, Georgia
-
LTD Krol Medical Corporation
RECRUITINGTbilisi, 0180, Georgia
-
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
RECRUITINGTbilisi, 0180, Georgia
-
Orlando Gastroenterology, P.A.
RECRUITINGOrlando, Florida, 32835, United States
-
PMSI "Timofei Mosneaga" Republican Clinical Hospital
RECRUITINGChisinau, MD2025, Moldova
-
Peters Medical Research
RECRUITINGHigh Point, North Carolina, 27260, United States
-
Southern Star Research Institute
RECRUITINGSan Antonio, Texas, 78229, United States
-
Tropical Clinical Trials
RECRUITINGPalmetto Bay, Florida, 33176, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame ulcerative colitis?
- Can a Real-World study reveal the staying power of guselkumab?
- Can a new biologic calm the immune attack in ulcerative colitis?
- Can better detection of precancerous lesions in IBD prevent colorectal cancer?
- Dutch hospital data reveals hidden patterns in IBD treatment
- Kids' metabolism under the microscope: new study on IBD and energy burn